GlaxoSmithKline plc (NYSE:GSK) has been assigned a consensus recommendation of “Hold” from the twenty research firms that are covering the company, Marketbeat Ratings reports. Three research analysts have rated the stock with a sell rating, ten have given a hold rating and five have given a buy rating to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $37.71.

A number of equities research analysts have recently commented on the stock. Zacks Investment Research raised shares of GlaxoSmithKline from a “hold” rating to a “buy” rating and set a $46.00 price objective on the stock in a research note on Wednesday, October 18th. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of GlaxoSmithKline in a research report on Wednesday, October 18th. Morgan Stanley lowered GlaxoSmithKline from an “equal weight” rating to an “underweight” rating in a research report on Friday, September 8th. Bank of America lowered GlaxoSmithKline from a “buy” rating to a “neutral” rating in a research report on Thursday, October 26th. Finally, TheStreet upgraded GlaxoSmithKline from a “c+” rating to a “b” rating in a research report on Wednesday, October 25th.

In other news, major shareholder Plc Glaxosmithkline acquired 428,571 shares of the firm’s stock in a transaction on Monday, November 6th. The shares were bought at an average price of $14.00 per share, for a total transaction of $5,999,994.00. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 10.00% of the company’s stock.

A number of hedge funds have recently made changes to their positions in GSK. FinTrust Investment Advisory Services LLC purchased a new position in shares of GlaxoSmithKline during the 3rd quarter worth $401,000. Private Advisor Group LLC raised its holdings in shares of GlaxoSmithKline by 7.2% during the 3rd quarter. Private Advisor Group LLC now owns 77,976 shares of the pharmaceutical company’s stock worth $3,166,000 after acquiring an additional 5,212 shares during the period. San Francisco Sentry Investment Group CA raised its holdings in shares of GlaxoSmithKline by 110.3% during the 3rd quarter. San Francisco Sentry Investment Group CA now owns 8,749 shares of the pharmaceutical company’s stock worth $356,000 after acquiring an additional 4,589 shares during the period. Freestone Capital Holdings LLC raised its holdings in shares of GlaxoSmithKline by 11.9% during the 2nd quarter. Freestone Capital Holdings LLC now owns 94,008 shares of the pharmaceutical company’s stock worth $4,054,000 after acquiring an additional 10,017 shares during the period. Finally, Renaissance Technologies LLC raised its holdings in shares of GlaxoSmithKline by 112.1% during the 2nd quarter. Renaissance Technologies LLC now owns 9,338,000 shares of the pharmaceutical company’s stock worth $402,655,000 after acquiring an additional 4,935,900 shares during the period. Institutional investors own 9.81% of the company’s stock.

Shares of GlaxoSmithKline (GSK) traded up $0.07 during midday trading on Friday, hitting $36.86. 5,206,300 shares of the stock were exchanged, compared to its average volume of 7,090,933. The firm has a market cap of $91,340.00, a PE ratio of 28.57, a price-to-earnings-growth ratio of 2.11 and a beta of 0.97. GlaxoSmithKline has a twelve month low of $34.52 and a twelve month high of $44.53. The company has a quick ratio of 0.44, a current ratio of 0.64 and a debt-to-equity ratio of 2.96.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, January 11th. Stockholders of record on Friday, November 10th will be given a dividend of $0.5037 per share. This is a positive change from GlaxoSmithKline’s previous quarterly dividend of $0.49. The ex-dividend date is Thursday, November 9th. This represents a $2.01 dividend on an annualized basis and a dividend yield of 5.47%. GlaxoSmithKline’s dividend payout ratio (DPR) is 154.26%.

TRADEMARK VIOLATION NOTICE: This story was originally published by American Banking News and is owned by of American Banking News. If you are viewing this story on another website, it was illegally copied and republished in violation of United States & international trademark & copyright law. The original version of this story can be viewed at https://www.americanbankingnews.com/2018/01/05/glaxosmithkline-plc-gsk-given-average-recommendation-of-hold-by-brokerages.html.

GlaxoSmithKline Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.